Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Evelo Biosciences, Inc.    EVLO

EVELO BIOSCIENCES, INC.

(EVLO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
14.43(c) 15.48(c) 15.08(c) 14.02(c) 15.71(c) Last
311 906 266 625 350 849 275 901 172 267 Volume
+4.72% +7.28% -2.58% -7.03% +12.05% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -87,9 M - -
Net cash position 2020 126 M - -
P/E ratio 2020 -6,94x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -107 M - -
Net cash position 2021 29,9 M - -
P/E ratio 2021 -7,59x
Yield 2021 -
Capitalization 726 M 726 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 98
Free-Float 92,8%
More Financials
Company
Evelo Biosciences, Inc. is engaged in developing therapies designed to act on gut-body network. The Company develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066, EDP1815, and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal... 
More about the company
Notations Surperformance© of Evelo Biosciences, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about EVELO BIOSCIENCES, INC.
01/20EVELO BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
01/20EVELO BIOSCIENCES : Reports Positive Data From Trial of Atopic Dermatitis Treatm..
MT
01/20Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial ..
GL
01/07EVELO BIOSCIENCES : Says EDP1815 Mid-Stage Program to Include Atopic Dermatitis;..
MT
01/07EVELO BIOSCIENCES : Expands Clinical Programs and Provides 2021 Guidance on Key ..
AQ
2020EVELO BIOSCIENCES : JMP Securities Starts Evelo Biosciences at Market Outperform..
MT
2020Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Dev..
GL
2020EVELO BIOSCIENCES, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2020EVELO BIOSCIENCES, INC. : Other Events (form 8-K)
AQ
2020Evelo Biosciences Selects EDP1908 as Lead Cancer Product Candidate After Prom..
MT
2020EVELO BIOSCIENCES : Announces New Clinical Candidate in Oncology and Presents Ad..
AQ
2020Evelo Biosciences Reports Positive Data From Trial of EDP1815 to Treat Atopic..
MT
2020EVELO BIOSCIENCES : Reports Positive Topline Clinical Data in Phase 1b Trial of ..
AQ
2020Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial of ..
MT
2020Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Eva..
GL
More news
News in other languages on EVELO BIOSCIENCES, INC.

- No features available -

More news
Analyst Recommendations on EVELO BIOSCIENCES, INC.
More recommendations
Stock Trading Strategies
EVELO BIOSCIENCES, INC. - 2020
No turn-around in sight
BUY
More Stock Trading Analysis
Chart EVELO BIOSCIENCES, INC.
Duration : Period :
Evelo Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVELO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 17,50 $
Last Close Price 15,71 $
Spread / Highest target 71,9%
Spread / Average Target 11,4%
Spread / Lowest Target -30,0%
EPS Revisions
Managers and Directors
NameTitle
Balkrishan Gill President, Chief Executive Officer & Director
David R. Epstein Chairman
Mark Bodmer Chief Scientific Officer, President-R&D
Duncan McHale Chief Medical Officer
Chun Zhang Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
EVELO BIOSCIENCES, INC.29.94%726
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148